Direct oral anticoagulants
101 results
1 - 100
Increased bleeding with switch from warfarin to direct oral anticoagulant in frail elderly (FRAIL-AF)- Higher risk of bleeding events associated with concomitant use of amiodarone and direct oral anticoagulants
- Direct oral anticoagulants associated with better outcomes than warfarin in older patients with stroke and AF (PROSPER)
- Direct oral anticoagulants (DOACs) plus clarithromycin associated with higher risk of bleed than DOACs plus azithromycin
- Direct oral anticoagulants are noninferior to low-molecular-weight heparin to prevent recurrent VTE in adults with cancer
- The DOAC score determines bleeding risk for patients with atrial fibrillation who take a direct-acting oral anticoagulant
- Early initiation of direct oral anticoagulants after acute stroke with atrial fibrillation is at least as good as later initiation
- Benefits and harms with oral anticoagulation for atrial fibrillation in patients with history of intracranial hemorrhage (COCROACH)
- Benefits/harms of novel oral anticoagulants similar in general population and the elderly
- ACCP guidelines for antithrombotics in atrial fibrillation
- Concomitant use of oral anticoagulants and SSRIs associated with increased risk of major bleeding
- No benefit to continuing perioperative oral anticoagulation for patients undergoing transcatheter aortic-valve implantation
- Adults with atrial fibrillation who survive ICH and resume DOACs have fewer strokes but more recurrent ICH (PRESTIGE-AF)
- For device-detected atrial fibrillation, anticoagulation decreases stroke risk (NNT = 100), increases major bleeding (NNTH = 62)
- Elevated INR (> 1.5) at admission associated with increased mortality in hospitalized patients who use DOACs
- Extended anticoagulation may be helpul for patients with unprovoked VTE or PE
- Updated American College of Chest Physicians guideline on antithrombotic therapy for venous thromboembolism
- Resuming oral anticoagulants after a bleed is associated with fewer thrombi and deaths, but more bleeds
- Aspirin no different than rivaroxaban for prevention of VTE after TKA or THA
- Abelacimab has fewer bleeds than rivaroxaban, but study has several important biases
- Use of antithrombotic medications increases risk of hematuria-related complications
- Dabigatran safe and effective for VTE
- Anticoagulant therapy for 6 weeks is noninferior to 3 months for provoked VTE in patients younger than 21 years (Kids-DOTT)
- Early anticoagulation after ischemic stroke is a safe strategy (ELAN)
- Greater benefit with rivaroxaban than aspirin for extended treatment of VTE
- For stable coronary artery disease plus atrial fibrillation, rivaroxaban alone is better than rivaroxaban plus aspirin
- Screening for atrial fibrillation in primary care is not effective (VITAL-AF)
- ACC/AHA guidelines for the diagnosis and management of atrial fibrillation
- Rivaroxaban is noninferior to warfarin for valvular atrial fibrillation; also associated with fewer strokes
- In adults with atrial fibrillation and acute ischemic strokes, early (within 4 days) and delayed (7-10 days) initiation of DOACs have similar outcomes (OPTIMAS)
- Guidelines for the perioperative management of anticoagulants and antiplatelet agents (ACCP)
- Older patients with atrial fibrillation treated with DOACs have fewer strokes and systemic emboli than those treated with vitamin K antagonists
- Rivaroxaban effective for acute DVT (EINSTEIN)
- Edoxaban noninferior to warfarin for venous thromboembolism anticoagulation
- Bleeding risk scores lack accuracy in primary care settings (CACAO)
- ACG guideline on managing acute lower gastrointestinal bleeding
- Edoxaban as effective as LMWH for treatment of cancer-associated VTE
- Warfarin provides greater net benefit than rivaroxaban for patients with atrial fibrillation and rheumatic heart disease
- Greater risk of serious bleeding with diltiazem vs metoprolol in adults with atrial fibrillation using apixaban or rivaroxaban
- Dabigatran cost-effective for AF prophylaxis in some patients, not others
- Extended rivaroxaban prophylaxis following a medical inpatient stay does not provide a net benefit (MARINER)
- Apixaban is noninferior to dalteparin for venous thromboembolism associated with cancer
- Rivaroxaban similar to warfarin for patients with NVAF
- For atrial fibrillation with stable coronary artery disease, edoxaban alone prevents more bad outcomes than edoxaban plus an antiplatelet agent
- Optimal treatment of acute venous thromboembolism